Holen Sie sich die Stockscreener-App
1.31
3.97%
0.05
Handel nachbörslich:
1.31
Schlusskurs vom Vortag:
$1.26
Offen:
$1.31
24-Stunden-Volumen:
2.63M
Relative Volume:
2.01
Marktkapitalisierung:
$101.66M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.5038
EPS:
-2.6
Netto-Cashflow:
$-175.17M
1W Leistung:
+11.02%
1M Leistung:
+50.92%
6M Leistung:
+24.76%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.2908
$1.39
1-Wochen-Bereich:
$1.13
$1.39
52-Wochen-Spanne:
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
Firmenname
Coherus Oncology Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Vergleichen Sie CHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.31 | 138.31M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-16 | Herabstufung | UBS | Buy → Neutral |
| 2023-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-07-24 | Eingeleitet | Citigroup | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-03-28 | Hochstufung | UBS | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Neutral |
| 2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Eingeleitet | BofA Securities | Neutral |
| 2020-04-17 | Eingeleitet | SunTrust | Buy |
| 2019-08-13 | Eingeleitet | Mizuho | Buy |
| 2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-02 | Bestätigt | Maxim Group | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-09 | Bestätigt | Maxim Group | Buy |
| 2017-08-08 | Bestätigt | JP Morgan | Overweight |
| 2017-06-13 | Bestätigt | Maxim Group | Buy |
| 2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-09-07 | Eingeleitet | Maxim Group | Buy |
| 2016-07-27 | Eingeleitet | Citigroup | Buy |
| 2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
RSI Reset May Fuel Rebound in Coherus BioSciences Inc.July 2025 Sector Moves & Technical Pattern Recognition Alerts - beatles.ru
Coherus Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Leader Coherus Oncology Sets Major Conference Schedule: Baird, Wainwright, and UBS Events - Stock Titan
Backtesting results for Coherus BioSciences Inc. trading strategiesJuly 2025 Trends & Real-Time Market Sentiment Alerts - Newser
Can machine learning forecast Coherus BioSciences Inc. recoveryTrade Analysis Summary & Safe Capital Allocation Plans - Newser
Relative strength of Coherus BioSciences Inc. in sector analysisMarket Movement Recap & Daily Profit Focused Stock Screening - Newser
Coherus Oncology: On The Shaping Up (NASDAQ:CHRS) - Seeking Alpha
Penny Stocks to Watch: Lantronix and Coherus Oncology Among Top Picks - AInvest
Lobbying Update: $125,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2025 Earnings Call Transcript - Insider Monkey
Coherus Oncology’s Earnings Call Highlights Growth and Challenges - TipRanks
Analysts' Revenue Estimates For Coherus Oncology, Inc. (NASDAQ:CHRS) Are Surging Higher - 富途牛牛
Coherus Oncology's (CHRS) Strategic Reinvention: A High-Conviction Biotech Play for the Long Term - AInvest
Industry Analysts Just Upgraded Their Coherus Oncology, Inc. (NASDAQ:CHRS) Revenue Forecasts By 21% - simplywall.st
Need To Know: Analysts Are Much More Bullish On Coherus Oncology, Inc. (NASDAQ:CHRS) Revenues - Yahoo Finance
Coherus Oncology 2025 Q2 Earnings Strong Turnaround with 2404.5% Net Income Surge - AInvest
Coherus Oncology shares rise 4.07% premarket after Q2 revenue up 36%. - AInvest
Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips - Investing.com
Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa
Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com
Coherus Oncology Reports Strong Q2 2025 Growth - TipRanks
Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - 富途牛牛
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Coherus Oncology: Q2 Earnings Snapshot - San Antonio Express-News
Coherus Oncology Q2 2025: LOQTORZI revenue up 36% to $10.0mln. - AInvest
Coherus Oncology Reports Second Quarter 2025 Financial Results a - GuruFocus
Coherus Oncology Reports 36% Increase in LOQTORZI Net Revenue for Q2 2025 and Updates on Pipeline Progress - Quiver Quantitative
Insights Ahead: Coherus BioSciences's Quarterly Earnings - 富途牛牛
Coherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by institutional shareholders who own 54% of the company - Yahoo Finance
Coherus Oncology Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
What is Coherus BioSciences Inc. company’s growth strategyLightning-fast capital gains - Jammu Links News
Earnings Preview: CHRS to Report Financial Results Post-market on August 07 - 富途牛牛
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 | CHRS Stock News - GuruFocus
Coherus Oncology to Release Second Quarter 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Coherus Earnings: Q2 2025 Results and Management Call Set for August 7 After Market Close - Stock Titan
Why Coherus BioSciences Inc. stock attracts strong analyst attentionHigh Reward Risk Balanced Trading - metal.it
Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35% - simplywall.st
Positive week for Coherus Oncology, Inc. (NASDAQ:CHRS) institutional investors who lost 47% over the past year - simplywall.st
Alvotech: A Fast Expanding Biosimilar Concern (NASDAQ:ALVO) - Seeking Alpha
Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Are Reducing Their Forecasts For This Year - 富途牛牛
Coherus Biosciences Receives Nasdaq Deficiency Notice - TipRanks
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? - Yahoo Finance
Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada
Coherus Oncology reports annual meeting results - Investing.com
Finanzdaten der Coherus Oncology Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):